identified the importance of exploring NAF for established biomarkers such as urokinase‐dependent plasminogen activator (uPA) and plasminogen activator inhibitor (PAI‐I), particularly for their role in ECM turnover associated with cancer invasiveness 30. The gene discussed is SERPINB2; the disease is cancer.